- Home
- ANEB vs CGTX Comparison
ANEB vs CGTX Comparison
Compare ANEB & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- CGTX
- Stock Information
- Founded
- ANEB 2020
- CGTX 2007
- Country
- ANEB United States
- CGTX United States
- Employees
- ANEB N/A
- CGTX N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- ANEB Health Care
- CGTX Health Care
- Exchange
- ANEB Nasdaq
- CGTX Nasdaq
- Market Cap
- ANEB 79.9M
- CGTX 79.3M
- IPO Year
- ANEB 2021
- CGTX 2021
- Fundamental
- Price
- ANEB $1.93
- CGTX $0.47
- Analyst Decision
- ANEB Buy
- CGTX Buy
- Analyst Count
- ANEB 1
- CGTX 6
- Target Price
- ANEB $8.00
- CGTX $8.00
- AVG Volume (30 Days)
- ANEB 13.3K
- CGTX 614.1K
- Earning Date
- ANEB 11-12-2024
- CGTX 10-31-2024
- Dividend Yield
- ANEB N/A
- CGTX N/A
- EPS Growth
- ANEB N/A
- CGTX N/A
- EPS
- ANEB N/A
- CGTX N/A
- Revenue
- ANEB N/A
- CGTX N/A
- Revenue This Year
- ANEB N/A
- CGTX N/A
- Revenue Next Year
- ANEB N/A
- CGTX N/A
- P/E Ratio
- ANEB N/A
- CGTX N/A
- Revenue Growth
- ANEB N/A
- CGTX N/A
- 52 Week Low
- ANEB $1.72
- CGTX $0.34
- 52 Week High
- ANEB $3.30
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- ANEB 49.10
- CGTX 45.81
- Support Level
- ANEB $1.83
- CGTX $0.40
- Resistance Level
- ANEB $1.96
- CGTX $0.53
- Average True Range (ATR)
- ANEB 0.08
- CGTX 0.04
- MACD
- ANEB 0.00
- CGTX 0.02
- Stochastic Oscillator
- ANEB 49.09
- CGTX 69.32
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.